Additionally, exploring the combined use of SGLT-2 inhibitors with other HF treatments (such as ACEI/ARBs, β-blockers, and aldosterone receptor antagonists) is essential for optimizing treatment regimens. The gene discussed is NR3C2; the disease is hydrops fetalis.